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Background: Transcription factor CP2 (TFCP2) is overexpressed in hepatocellular carcinoma(HCC) and correlated
with the progression of the disease. Here we report the use of an integrated systems biology approach to identify
genome-wide scale map of TFCP2 targets as well as the molecular function and pathways regulated by TFCP2
in HCC.
Methods: We combined Chromatin immunoprecipitation (ChIP) on chip along with gene expression microarrays to
study global transcriptional regulation of TFCP2 in HCC. The biological functions, molecular pathways, and networks
associated with TFCP2 were identified using computational approaches. Validation of selected target gene
expression and direct binding of TFCP2 to promoters were performed by ChIP -PCR and promoter reporter.
Results: TFCP2 fostered a highly aggressive and metastatic phenotype in different HCC cells. Transcriptome analysis
showed that alteration of TFCP2 in HCC cells led to change of genes in biological functions involved in cancer,
cellular growth and proliferation, angiogenesis, cell movement and attachment. Pathways related to cell movement
and cancer progression were also enriched. A quest for TFCP2-regulated factors contributing to metastasis, by
integration of transcriptome and ChIP on chip assay, identified fibronectin 1 (FN1) and tight junction protein 1 (TJP1) as
targets of TFCP2, and as key mediators of HCC metastasis. Promoter reporter identified the TFCP2-responsive region,
and located the motifs of TFCP2-binding sites in the FN1 promoter, which then was confirmed by ChIP-PCR. We further
showed that FN1 inhibition blocks the TFCP2-induced increase in HCC cell aggression, and that overexpression of
TFCP2 can rescue the effects of FN1 inhibition. Knock down of TJP1 could also rescue, at least in part, the aggressive
effect of TFCP2 knockdown in HCC cells.
Conclusions: The identification of global targets, molecular pathways and networks associated with TFCP2,
together with the discovery of the effect of TFCP2 on FN1 and TJP1 that are involved in metastasis, adds to our
understanding of the mechanisms that determine a highly aggressive and metastatic phenotype in
hepatocarcinogenesis.
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In the past decade hepatocellular carcinoma (HCC) has
gone from being almost universally fatal, to a cancer that
could be prevented, detected at an early stage and effect-
ively treated [1,2]. However, due to the high incidence and
inadequate surveillance, HCC remains the third most com-
mon cause of cancer-related mortality with about 600,000
patients dying annually from this aggressive disease around
the world [3,4]. In China with the high prevalence of
hepatitis B virus (HBV) infection, HBV-related HCC has
become one of the main disease burdens. Intrahepatic or
distant metastases at the time of diagnosis preclude many
patients of the chance of surgery. Various factors such as
microRNAs and transcription factors, contribute to metas-
tasis by inducing HCC cell epithelial-mesenchymal transi-
tion (EMT), which is characteristic for the most aggressive
metastatic cancer cells [5-8].
The transcription factor CP2 (TFCP2) has been shown
to regulate diverse cellular and viral promoters, and plays
roles in cell cycle progression and cell survival, as well as
in cell lineage-specific functions, shown most strikingly to
date in hematopoietic lineages [9-12]. TFCP2 is required
for Snail1-induced Fibronectin (FN1) expression during
EMT [13]. Yoo et al. [14] documented that TFCP2 overex-
pression is detected in more than 90% cases of human
HCC patients compared to normal liver, and associated
with the stage and grade of the disease. To better under-
stand the molecular mechanisms by which TFCP2 con-
tributes to cancer progression, researchers have identified
and characterized several downstream target genes that
are directly regulated by the TFCP2. These include osteo-
pontin (OPN) and matrix metalloproteinase-9 (MMP-9)
[14,15]. In addition, TFCP2 contributes to cell survival
and cell cycle regulation by regulating the expression of
thymidylate synthase (TS) [16]. Since TS is the target of 5-
fluorouracil, TS up-regulation as a consequence of TFCP2
overexpression leads to 5-fluorouracil resistance [17]. The
pivotal role of TFCP2 in hepatocarcinogenesis and che-
moresistance indicates that TFCP2 inhibition might be an
effective therapeutic approach for treating HCC. There-
fore, the successful development of TFCP2 inhibitors will
be potential for HCC chemotherapy but also rely on the
clear mechanisms of TFCP2 signaling in HCC.
In this study, we identified TFCP2-related biological
functions and pathways in HCC in different cellular
contexts using Ingenuity Pathway Analysis (IPA). An
integrated analysis of transcriptome and Chromatin
immunoprecipitation (ChIP) on chip in HCC cells was
used to screen for genes whose mRNA levels were regu-
lated by TFCP2, and whose promoters were bound by
TFCP2. We identified FN1 as a direct TFCP2 target,
tight junction protein 1 (TJP1) as an indirect target,
both as markers of EMT and key mediators of TFCP2 in
HCC metastasis. This together with elucidation of directtargets of TFCP2 and genome-wide identification of
targets and molecular pathways associated with TFCP2,
will provide insights into its function and lead to better
understanding of its role in hepatocarcinogenesis.
Materials and methods
Cell culture
Human HCC cell lines SMMC-7721, HepG2, Hep3B,
SK-HEP-1, BEL-7402, Huh7, and MHCC-LM3 were pur-
chased from Institute of Biochemistry and Cell Biology,
Chinese Academy of Sciences (Shanghai, China) and main-
tained in Dulbecco’s modified Eagle’s medium (DMEM) or
RPMI 1640 medium (Gibco, CA, USA) supplemented with
10% fetal bovine serum (Gibco, CA, USA) in a 37°C incu-
bator with 5% CO2.
Transfection with small interfering RNA and expression
vectors
Negative control small interfering RNA (siRNA) and
specific siRNA (siTFCP2: 5′-GCCAUUCCGAGUACA
AAUATT-3′, siFN1: 5′-CUCUUGUGGCCACUUCUG
ATT-3′) and siTJP1: 5′- GGGCUCUUGGCUUGCU
AUUCGAATT-3′ were synthesized by Genepharma Corp
(Shanghai, China). Cells were transfected with siRNA by
Lipofectamine 2000 (Invitrogen, CA, USA). The HCC
cells were used for real-time PCR, western blot, and gene
chip after treating with siRNA for 48 h, used for migration
and invasion after treating with siRNA for 24 h.
A hemagglutinin (HA) tag was inserted by restriction
enzyme digestion onto the 3′ end of a TFCP2 cDNA
clone. The resulting TFCP2-HA open reading frame was
subcloned into lentivirus vector. The virus was produced
in HEK293T transfected with either empty vector or the
TFCP2-HA-containing construct along with the pack-
aging helper plasmids, pRsv-Rev, MDLg/pRRE, pMD2.G.
Virus was used to infect cells with 5 μg/mL polybrene.
Stable cells were selected with 1 μg/mL puromycin in
DMEM medium supplemented with 10% FBS.
Cell proliferation assays, colony formation assays, and
migration and invasion assays
Cell proliferation assays, colony formation, and migra-
tion and invasion assays were performed as described
previously [18]. The assays were performed in triplicate
after knockdown or overexpression of TFCP2 in the
cells, respectively.
Real-time PCR, western blotting
Real-time PCR was carried out using a ABI 7500 fast
real-time PCR system as described previously [19].
Western blotting was performed and analyzed as de-
scribed previously [18]. The primers for real-time PCR
and the antibodies used for western blotting are listed in
Additional file 1: Table S1 and Table S2, respectively.
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Total RNA from HepG2 cells after knockdown of
TFCP2 was isolated using Trizol (Invitrogen, CA, USA)
according to a standard protocol, and was further puri-
fied with RNeasy Mini Kit (Qiagen, Valencia, CA, USA).
A Roche NimbleGen Microarray (Human Expr 12x135K
Arr Del) was used to analyze the transcriptome after the
alteration of TFCP2. The siRNA experiment arrays were
run in triplicate. Significantly up-regulated and down-
regulated genes were defined by a 2-fold change from
controls (P < 0.05 and FDR < 0.1).Chromatin immunoprecipitation (ChIP) on chip analysis
Antibodies that specifically immunoprecipitate TFCP2 are
not currently available. We, therefore, established SK-HEP-
1 cells that stably expressed TFCP2-HA for use in ChIP
experiments. ChIP were performed using Chromatin
Immunoprecipitation Kit (Merck Millipore) according to
the instructions. The immunoaffinity-enriched DNA was
proceeded for Nimblegen human promoter array assays or
ChIP-PCR. The DNA isolated from ChIP with HA anti-
body from the TFCP2-HA-SK-HEP-1 cells, along with an
input control, was amplified using linker-mediated PCR.
Amplified DNA was labeled and hybridized to the Nimble-
gen human 3x720K RefSeq promoter array. The data from
each hybridization was Z-score normalized, and the ratios
of immunoprecipitation to input signal were determined.
ChIPOTle analysis was performed for each array to identify
peaks, using a sliding window approach.Construction of luciferase reporter plasmids
The human FN1 promoter region (−2000/+200) was ob-
tained by PCR, using genomic DNA from BEL-7402 cells
as a template. A series of 5′-deletion fragments of the
FN1 promoter were generated by PCR using the primers
shown in Additional file 1: Table S1. This was subcloned
into KpnI (MluI)/XhoI sites of the pGL3-basic vector
(Promega, Wisconsin, USA). All constructs were verified
by sequencing.Promoter reporter assays
Cells were seeded in 24-well plates, grown to 60%
confluence, and transfected using Lipofectamine 2000
according to manufacturer’s manual. In brief, each well
was transfected with 400 ng of reporter constructs and
20 ng of pRL-TK plasmid (Promega, Wisconsin, USA)
which was used to monitor transfection efficiency. At
48 h post-transfection, firefly luciferase activity was
measured using a dual-luciferase reporter assay system
(Promega, Wisconsin, USA). For siRNA transfection,
cells were transfected with siRNA for 24 h and further
transfected with plasmids.Results
TFCP2 enhances HCC cell growth
TFCP2 protein expression was detected in human HCC
cell lines by real-time PCR and western blotting (Figures 1A
and B). The results showed that HepG2, BEL-7402, and
MHCC-LM3 were associated with high TFCP2 expression,
and Hep3B and SK-HEP-1 cell lines were characterized by
low TFCP2 expression. To determine the effect of TFCP2
on HCC growth and aggressiveness, we constructed
human HCC cell lines (HepG2 and BEL-7402) with
depleted TFCP2 using siRNA. We also constructed cell
lines (Hep3B and SK-HEP-1) with stable TFCP2-HA over-
expression using lentivirus. Successful alterations of TFCP2
expression in these cells were confirmed by western blot-
ting (Figures 1C and D).
Knockdown of TFCP2 significantly inhibited tumor cell
growth in HepG2 and BEL-7402 cells compared with the
control cells. By contrast, overexpression of TFCP2 signifi-
cantly increased the growth of Hep3B and SK-HEP-1 cells
(Figures 1E and F). Colony-formation assays were per-
formed in cells with altered TFCP2 expression. As shown
in Figures 1G and H, knockdown of TFCP2 resulted in
significantly lower colony formation efficiency in HepG2
(10.12 ± 6.6% vs 42.25 ± 7.8%) and BEL-7402 cells (8.20 ±
5.0% vs 36.50 ± 5.4%) relative to control cells (P < 0.01). By
contrast, TFCP2 overexpression resulted in significantly
higher colony formation efficiency in SK-HEP-1 and
Hep3B cells than in control cells (P < 0.01). These findings
suggest that TFCP2 signaling enhances the colony forma-
tion capacity of HCC cells.
TFCP2 enhances HCC cell aggressiveness
Since migratory and invasive behaviors are indicators of
the metastatic potential, we performed migration and in-
vasion assays to examine the impact of TFCP2 on HCC
cell aggressiveness. The TFCP2-knockdown HepG2 cells
migrating toward the conditioned medium or invading
through the matrigel were significantly lower than con-
trols in the migration (69.1 ± 21.2 vs 179.4 ± 28.7) and
invasion assay (62.4 ± 16.1 vs 210.3 ± 26.5). They were
higher than controls in TFCP2-overexpressed SK-HEP-1
cells. The results are shown in Figure 2. Similar changes
in cell aggressiveness pattern were observed in BEL-7402
or Hep3B cells after corresponding alterations of TFCP2
(Additional file 2: Figure S1). These findings suggest that
TFCP2 may be an important contributor to the migration
and invasion of HCC cells.
Genes and biological functions that respond to TFCP2
alteration in HCC cells
Gene expression array analysis was performed in HepG2
cells after knockdown of TFCP2. Statistical analysis
performed in the transcriptome dataset showed that in
HepG2, 454 genes were significantly down-regulated and
Figure 1 (See legend on next page.)
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Figure 1 TFCP2 promotes human HCC cell growth, in vitro. (A) Real-time PCR and (B) western blotting for TFCP2 expression in human HCC
cell lines, Red and blue bars represent high and low TFCP2 expression in HCC cells, respectively in A. β-actin as a loading control. (C, D) Western
blotting of TFCP2 changes in HCC cells after siRNA transfection for 48 h or lentivirus infection. (C) Decreased TFCP2 protein in HepG2 and
BEL-7402 cells transfected with siTFCP2 compared with negative control (siNC), (D) Increased TFCP2-HA fusion protein in Hep3B and SK-HEP-1
cells with lentivirus infection compared with negative control (Lenti-NC). (E, F) Cell proliferation assays in HCC cells with altered TFCP2 expression.
The cell viability was determined by the CCK-8 assay in 96-well plates. All determinations were performed at least in seven replicates in three
independent experiments. Values represent O.D. values mean ± SD (*P < 0.05, **P < 0.01; upper, HepG2 or SK-HEP1, lower, BEL-7402 or Hep3B).
(E) HepG2 and BEL-7402 cells transfected with siRNA (F) Hep3B and SK-HEP-1 cells with lentivirus infection. (G, H) Colony formation assays in
HCC cells with altered TFCP2 expression in cell culture plates. Representative photographs of colony formation from different cell lines are shown
in the upper panels. The colony formation rate is shown in the lower panels (calculated by dividing the colony numbers by the plated cells). Data
were obtained from three independent experiments. (G) HepG2 and BEL-7402 cells transfected with siRNA for 24 h and then used for colony
assays, (H) Hep3B and SK-HEP-1 cells with lentivirus infection (**P < 0.01).
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(>2.0-fold change). We validated these data using real-
time PCR in nine genes randomly obtained after alteration
of TFCP2 in HepG2, representing all three expression
patterns (up-regulated, unchanged, and down-regulated).
Good concordance was observed between the results from
real-time PCR and those from the cDNA array (AdditionalFigure 2 The effect of TFCP2 on cell migration and invasion. The TFCP
invasion of HCC cells compared with controls, HepG2 transfected with siRN
overexpression in SK-HEP-1 promoted migration and invasion. The migratio
Representative fields of invaded cells from independent groups are shown
the lower panels. The data are presented as mean ± SD of three different efile 2: Figure S2). The complete data from the transcrip-
tome analysis is shown in Additional file 3: Table S3. IPA
was undertaken to identify TFCP2-relevant biological
functions from differentially expressed genes in each
cell line. The top 7 significant functional classification
of TFCP2-regulated genes, ranked by P-value are shown
in Table 1. Notably, among these significant functions,2 knockdown in HepG2 significantly inhibited the migration and
A for 24 h and then used for miagration and invasion. Whereas TFCP2
n and invasion assays were assessed at 24 and 48 h, respectively.
in the upper panels. Quantitative analysis of invaded cells is shown in
xperiments (*P < 0.01).
Table 1 Bio-function analysis of the TFCP2-regulated genes in HepG2 knock down of TFCP2
Category Functions P-Value Activation State† z-score† #Molecules§
Cancer Growth 2.81E-07 −0.508 28
Cellular assembly and organization Adhesion 5.47E-07 11
Cell-To-Cell Signaling and Interaction Binding 1.15E-06 Decreased −2.412 6
Cardiovascular System Development
and Function
Angiogenesis 1.22E-05 Decreased −2.297 32
Cellular Movement Cell movement of carcinoma
cell lines
6.24E-05 Decreased −2.252 11
Cell-To-Cell Signaling and Interaction Attachment of cells 1.93E-04 Decreased −2.412 7
Cellular Movement Chemotaxis of tumor cell lines 1.17E-03 Decreased −2.036 10
†Activation State & z-score, z-score was calculated by the IPA z-score algorithm, reflecting the predicted direction of change for the function, an absolute z-score
of ≥ 2 is considered significant. Activation State is: Increased if the z-score is ≥ 2, Decreased if the z-score ≤ −2, Blank (empty) - IPA does not make a prediction for
the process or disease. §The number of molecules (genes) that are associated with each function.
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served in HepG2 after TFCP2 knockdown.
Identification of TFCP2 direct target genes by ChIP on chip
We used a ChIP on chip assay in TFCP2-HA-SK-
HEP-1cells, using the 3x720K RefSeq promoter array
(NimbleGen), to identify genes that were directly regu-
lated by TFCP2. Our results showed that a total of 1095
promoters were enriched by ChIP on chip (FDR ≤0.01,
peak-score >0.50) (Additional file 4: Table S4). Interest-
ingly, the 1095 direct targets were most enriched from
gene functions involved in cancer, gastrointestinal disease
and respiratory disease. Other prominent functions were
cell-to-cell signaling and interaction, drug metabolism,
embryonic and organism development, and cell morph-
ology (Additional file 2: Figure S3). By integrating TFCP2-
ChIP targets with the TFCP2-regulated transcriptome, 25
overlapped genes are listed in Additional file 1: Table S5,
which also contains the results of validation by real-time
PCR with 4 cell lines.
IPA was used to identify the signal pathways associated
with the TFCP2-ChIP targets in TFCP2-HA-SK-HEP-
1and TFCP2-regulated genes from gene arrays in HepG2.
Based on ChIP on chip in TFCP2-HA-SK-HEP-1cells, the
most important signal pathways were factors promoting
cardiogenesis, heparin sulfate biosynthesis, and chondro-
itin sulfate biosynthesis (Figure 3A). In HepG2 cells, 3-
phosphoinositide biosynthesis, rac signaling, and mitotic
roles of polo-like kinase were identified as important path-
ways after knockdown of TFCP2 (Figure 3B). Pathways 6,
and 8 based on ChIP on chip in TFCP2-HA-SK-HEP-1
were associated with cancer, and pathways 2, 6, and 8 in
HepG2 cells were associated with cell adhesion and
motility related pathways. This finding supports a possible
role of these newly identified targets of TFCP2 in HCC
progression and other biological processes.
Networks were created using IPA to interpret differen-
tially expressed gene interactions in HCC cells. The scores,
derived from P-values, indicated the likelihood of focusgenes belonging to a network. In HepG2 cells, the top
three networks (scores = 34, 34, 30, respectively) were in-
volved in protein synthesis/degradation, cellular assembly,
cancer, and cell cycle (Additional file 2: Figure S4).
TFCP2 signaling in migration/invasion of HCC cells
To test which genes mediated TFCP2-promoting migra-
tion/invasion of HCC, we focused on the markers of
EMT by integrating TFCP2-ChIP targets with the TFCP2-
regulated transcriptome (Additional file 1: Table S5).
Among the common genes identified by both TFCP2-ChIP
targets and TFCP2-regulated transcriptome, FN1 and TJP1
were selected for further characterization on the basis of
their relatively high binding intensity in the ChIP on chip
and the fact that they are important makers of EMT that
mediates the migration/invasion of different cancer cells
[20,21]. In accordance with FN1 and TJP1 roles in aggres-
sive metastatic cancer cells, the former promotes and the
latter suppresses the cancer cell aggression, western blot-
ting demonstrated that FN1 was positively regulated and
TJP1 was negatively regulated by TFCP2 in human HCC
cells (Figure 4A). Furthermore, we also validated whether
other markers of EMT were indirectly regulated by TFCP2,
as they were not enriched in ChIP on chip. As showed in
Figure 4B, N-cadherin, E-cadherin, slug, and snail were not
affected by TFCP2.
TFCP2 activates the FN1 promoter
To explore molecular mechanisms by which TFCP2 in-
duces FN1 expression, we cloned ~2 kb region of human
FN1 gene starting from −2000 to +200, where the trans-
lation start site was regarded as +1. FN1-Prom-luc
(−2000/+200) was transfected into cells together with a
renilla TK plasmid. Firefly luciferase activity was normal-
ized by renilla luciferase activity. TFCP2-overexpression
significantly increased FN1 promoter activity in SK-HEP-1
cells, and TFCP2-knockdown significantly decreased FN1
promoter activity in BEL-7402 cells (Figure 5A). The same
promoter assay was used to TJP1, however TFCP2 didn’t
Figure 3 Signal pathways of the TFCP2 target genes. Microarray and ChIP on chip data grouped by signal pathways ranked in order of
statistical significance. The ratio of genes (orange line) refers to number of genes involved in a pathway divided by total genes. Data and images
were generated using Ingenuity Pathways Analysis. The most important signal pathways were based on ChIP on chip data in SK-HEP-1 cells (A),
and gene array data in HepG2 after knockdown of TFCP2 (B).
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shown). TJP1 may be regulated indirectly by TFCP2. Next,
we selected FN1 for further characterization.
To delineate the region(s) of the FN1 promoter that
were induced by TFCP2, we attempted to delete the pro-
moter region (Figure 5B). Successive 5′-deletions from
positions −2000 to −471 resulted in, at most, moderate
changes in FN1 promoter activity induced by TFCP2 in
SK-HEP-1. However, elimination of the region from-471
to −272 resulted in a marked decrease in TFCP2-induced
FN1 promoter activity, indicating that the four potential
TFCP2 binding elements between −471 and −271 contrib-
ute to TFCP2 responsiveness. Analysis of this FN1 pro-
moter region identified the potential TFCP2-binding
consensus of four base motifs separated by a linker of five
to six bases (CNRG-N5–6-CNRG/C) (Figure 5C). This is
consistent with reports for other members of the CP2
family [22,23]. As such we designed two sets of PCR
primers around the promoter between −471 and −271,
the first pair flanking the TFCP2 potential binding sites
(fragment A), while the other pair not (fragments B), to
confirm direct binding of TFCP2 to FN1 promoter byFigure 4 TFCP2 positively regulates FN1 and negatively regulates TPJ1
HepG2 and BEL-7402 cells after TFCP2-knockdown (treated with siTFCP2 for 4
Western blot analysis. Other markers of EMT (E-cadherin, N-cadherin, slug, andChIP. ChIP assay demonstrated TFCP2 binding only to
the proximal part with TFCP2-binding sites and not to the
distal part without (Figure 5D). These results confirm that
TFCP2 transcriptionally up-regulates FN1.
FN1 and TPJ1 mediate the TFCP2-induced increase in HCC
cancer cell aggression
As FN1 is a downstream activation target of TFCP2, we
predicted that FN1 inhibition could block the aggressive
effect caused by overexpression of TFCP2. To test this
prediction, we treated cells with FN1 siRNA with or with-
out TFCP2 overexpression. Cells infected by TFCP2 vec-
tors and transiently transfected with FN1 siRNA showed
no increase in aggression by TFCP2 overexpression. As
compared to transfection with the negative control, trans-
fection with the FN1 siRNA resulted in significant protec-
tion against the aggressive effect of TFCP2 overexpression
(Figure 6A). The same rescue experiments was performed
for TJP1.Transient transfection with TJP1 siRNA results
in a significant increase in migratory and invasive be-
haviors analyzed by migration and invasion assays. Cells
transfected by SiTFCP2 and TJP1 siRNA showed noin human HCC cells. FN1 and TJP1 protein expression was detected in
8 h) and in Hep3B and SK-HEP-1 cells after TFCP2-overexpression (A) by
snail) were not obvious regulated by TFCP2 (B).
Figure 5 Deletional analysis of the FN1 minimal promoter, and analysis of TFCP2-binding sites. (A) FN1 promoter activity in SK-HEP-1 and
BEL-7402 cells after the alteration of TFCP2. Firefly luciferase activity representing FN1 promoter activity was measured after transfection with
pFN1-2200 and normalized to Renilla luciferase activity. (B) Schematic representation of the FN1 promoter (and its fragmental constructs) and
transcription activation of FN1 promoter fragments by TFCP2. SK-HEP-1 control and overexpression cells were transfected with the deletion fragmental
constructs of the FN1 promoter and renilla TK plasmid for normalization. All determinations were performed at least in triplicate in three independent
experiments. Values represent mean ± SD. *P < 0.01. (C) The −471/-272 sequence of the FN1 promoter includes CNRG-N5–6-CNRG/C, as a putative site
for TFCP2 binding. The positions of potential regulatory motifs are indicated by rectangles. Consensus sequence is annotated, where N = T, C, A or G;
and R = A or G. (D) Schematic diagram of FN1 promoter showing the location of potential TFCP2-binding sites in the promoter and primers
designed for ChIP assay. Fragment A and B represent fragments with potential TFCP2-binding consensus or without, respectively. ChIP using
anti-IgG or anti-HA were performed with stable SK-HEP-1 cell lines expressing TFCP2-HA or not (empty vector) followed by PCR using primers
to the candidate target promoter regions of FN1.
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above results suggest that FN1 and TJP1 mediate, at
least in part, the aggressive effect of TFCP2 signal.
Discussion
TFCP2 is a ubiquitously expressed transcription factor
in mammalian cells [9]. Substantially enhanced expres-
sion of TFCP2 in hepatocellular carcinoma has been
shown to promote oncogenesis [14,24]. In agreement
with previous findings, we demonstrated that TFCP2
was critical in maintaining cellular matrigel invasion,
proliferation and metastasis [14]. In order to identify
TFCP2 binding targets on a genome-wide scale, we
performed ChIP for TFCP2 in a human HCC cell line
SK-HEP-1. Additionally, a global gene expression ana-
lyses was performed in HCC cells HepG2 after down-
alteration of TFCP2. We investigated a comprehensive
transcriptional network of genes under the control of
the transcription factor TFCP2 in HCC cell lines, and
identified the direct targets of TFCP2, as well as a
number of indirect targets that are affected TFCP2.Furthermore, FN1 and TJP1 were identified as the
TFCP2 target genes, mediating TFCP2-induced metas-
tasis in HCC.
IPA analysis shows that biological functions involving
growth, adhesion, binding, and angiogenesis and so on
are significantly enriched in the TFCP2 transcriptome in
HepG2 cells. As regard TFCP2-ChIP targets in SK-HEP-
1, the functions associated with cancer, cell movement,
cell cycle, cell-to-cell signaling and interaction, cellular
growth and proliferation were also significantly enriched.
These findings indicate that although cell lines from
different lineages can share common TFCP2-regulated
biological functions, the genes that are involved could be
quite distinct.
TFCP2 augments HCC progression and metastasis by
altering multiple physiologically important pathways. IPA
analysis of the direct and indirect targets of TFCP2 identi-
fied the pathways affected by changes in the expression
level of TFCP2 target genes. Interestingly, unlike the
biological functions, there are few common pathways
shared by the TFCP2-regulated genes in the two cell lines.
Figure 6 TFCP2 promotes migration/invasion through up-regulating FN1 and down-regulating TJP1. (A) FN1 inhibition partially reverses
the aggressive effect by TFCP2 overexpression in SK-HEP-1 and Hep3B cells. Transient transfection with FN1 siRNA results in a significant reduction
in migratory and invasive behaviors analyzed by migration and invasion assays (*, P < 0.05 compared with SiNC). Cells infected by TFCP2 vectors
and transiently transfected with FN1 siRNA showed no increase in aggression by TFCP2 overexpression (**, P > 0.05 compared with cells with
Lenti-NC + SiNC). (B) SiTJP1 could also rescue, at least in part, the aggressive effect of TFCP2 knockdown in HepG2 and BEL-7402 cells. Transient
transfection with TJP1 siRNA results in a significant increase in migratory and invasive behaviors analyzed by migration and invasion assays
(*, P < 0.05 compared with SiNC). Cells transfected by si-TFCP2 and TJP1 siRNA showed no reduction in aggression by si-TFCP2 (**, P > 0.05
compared with cells with SiNC + SiNC).
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chip or microarrays, most based on ChIP on chip in SK-
HEP-1 cells were associated with growth and develop-
ment, and the extracellular matrix. The pathways in
HepG2 cells after TFCP2 knockdown were associated
with cell adhesion and motility. These findings support
a possible role for these newly identified targets of TFCP2
in HCC progression and other biological processes.
Target genes of transcription factors are known to be
highly context- and cell type- specific. In this study, we
used SK-HEP-1 cells as an in-vitro screening tool for
identifying specific targets of TFCP2 binding in HCC.
While we believe that the majority of identified TFCP2
target genes in SK-HEP-1 cells are likely to be present in
other HCC cells. It is also plausible that binding targetsthat require TFCP2 and additional co-factors may not be
fully represented in our system. Because unique co-factors
present in distinct cell types are likely to play a significant
role in dictating DNA binding specificity and/or affinity of
the TFCP2 transcription complex.
Our experiments also established the presence of dir-
ect transcriptional regulation of FN1 by TFCP2. FN1 is a
typical mesenchymal gene involved in EMT [25]. Recent
studies have shown that FN1 can bind to collagen/gel-
atin, heparin, and cell surface receptors, and that it plays
an important role in cell adhesion, migration, and differ-
entiation [26,27]. It has also been shown that FN1 down-
regulation suppresses the migration and invasion [28,21].
Therefore, the demonstration that FN1 is a direct down-
stream target of TFCP2 establishes a new molecular
Xu et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:6 Page 10 of 11wiring which may, at least partially, explain how TFCP2
amplification contributes to HCC progression and metas-
tasis. Additionally, TJP1, as the TFCP2 indirect target,
mediates the TFCP2-promoting HCC progression. Our
findings also showed that the core promoter was found
from the human FN1 promoter region (−2000 to +200),
and contained the putative regulatory motifs (CNRG-
N5–6-CNRG/C). Inconsistent with the previous report
[13], we found the TFCP2 regulation on FN1 through
the same motifs. This further illustrates that TFCP2
regulates FN1 across different cell systems. Porta-de-la-
Riva et al. [13] found that FN1 was up-regulated upon
EMT induction by Snail1 in normal development, then
TFCP2 was found to bind the FN1 proximal promoter,
which responses to Snail1. In our paper, FN1 was se-
lected from ChIP on chip and array results of TFCP2 in
cancer (HCC), we used a series of 5′-deletion fragments
of the FN1 promoter (~2 kb region) to locate the
responsive minimal promoter to TFCP2 and found in-
volvement of TFCP2 in migration, as mediated through
its direct upregulation of FN1.
In conclusion, our data provide a comprehensive list
of the direct targets of TFCP2, and identify a number of
indirect targets that are affected by loss or gain of
TFCP2. We also investigated the transcriptional and mo-
lecular networks and associated pathways in HCC cells
as well as the effect of TFCP2 on FN1 and TJP1, major
player of HCC metastasis as well as key regulator of
mesenchymal cell phenotype. These findings provide a
molecular foundation for future studies aimed at under-
standing the mechanisms of TFCP2 signaling in hepato-
carcinogenesis. They may also facilitate the design of
TFCP2-based cancer therapy. Indeed, the availability of
small molecule inhibitors of TFCP2 may herald a novel
generation of anti-HCC agents with significant thera-
peutic potential and encourage further research into the
role of TFCP2.Additional files
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